NCT03798236View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

March 30, 2019

Study Completion Date

May 31, 2019

Conditions
Psoriasis
Interventions
DRUG

PBF-1650 oral capsules

Adenosine A3 receptor (AA3R) antagonist

DRUG

Placebo oral capsule

solid microcrystalline cellulose

Trial Locations (1)

31007

Clinica Universidad de Navarra, Pamplona

All Listed Sponsors
collaborator

Clínica Universidad de Navarra

UNKNOWN

lead

Palobiofarma SL

INDUSTRY

NCT03798236 - Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. | Biotech Hunter | Biotech Hunter